Abstract
AbstractSubjective cognitive decline (SCD) and mild cognitive impairment (MCI) accompanied by cerebrovascular risk factors (CVRFs) are known to increase the risk of developing dementia. Mind-body practices such as yoga and meditation, have been recognized as safe techniques with beneficial effects on cognitive functions in older adults at risk for cognitive decline. We conducted a randomized, controlled trial to assess the efficacy of Kundalini yoga training (KY) compared to memory enhancement training (MET) on mood and cognitive functioning in a group of older women with CVRFs and SCD (clinicaltrials.gov = NCT03503669). The KY intervention consisted of weekly, 60-min in-person classes with a certified instructor for 12 weeks, with a 12-min guided recording for daily homework practice at home. MET involved 12 weekly in-person group classes with 12-min daily homework exercises. Objective and subjective memory performance were the primary outcomes. Peripheral whole blood samples were collected at baseline, 12-weeks, and 24-weeks follow-up for RNA sequencing and cytokine/chemokine assays. A total of 79 patients (KY = 40; MET = 39) were randomized, and 63 completed the 24-week follow-up (KY = 65% completion rate; MET = 95%; χ2(1) = 10.9, p < 0.001). At 24-weeks follow-up, KY yielded a significant, large effect size improvement in subjective cognitive impairment measures compared to MET. KYOn a transcriptional level, at 12- and 24-week follow-up, KY uniquely altered aging-associated signatures, including interferon gamma and other psycho-neuro-immune pathways. Levels of chemokine eotaxin-1, an aging marker, increased over time in MET but not KY participants. These results suggest clinical and biological benefits to KY for SCD, linking changes in cognition to the anti-inflammatory effects of yoga.
Funder
U.S. Department of Health & Human Services | NIH | National Center for Complementary and Integrative Health
Alzheimer’s Research Foundation
Alzheimer’s Research and Prevention Foundation
Publisher
Springer Science and Business Media LLC
Reference57 articles.
1. Mendonca MD, Alves L, Bugalho P. From subjective cognitive complaints to dementia: who is at risk? A systematic review. Am J Alzheimers Dis Other Demen. 2016;31:105–14.
2. Schliep KC, Barbeau WA, Lynch KE, Sorweid MK, Varner MW, Foster NL, et al. Overall and sex-specific risk factors for subjective cognitive decline: findings from the 2015–2018 behavioral risk factor surveillance system survey. Biol Sex Differ. 2022;13:16.
3. de Rojas I, Romero J, Rodriguez-Gomez O, Pesini P, Sanabria A, Perez-Cordon A, et al. Correlations between plasma and PET beta-amyloid levels in individuals with subjective cognitive decline: the Fundacio ACE Healthy Brain Initiative (FACEHBI). Alzheimers Res Ther. 2018;10:119.
4. Buckley RF, Sikkes S, Villemagne VL, Mormino EC, Rabin JS, Burnham S. et al.Using subjective cognitive decline to identify high global amyloid in community-based samples: A cross-cohort study.Alzheimers Dement. 2019;11:670–8.
5. Lin KA, Roy Choudhury K, Petrella JR, Doraiswamy PM. P4‐108: Marked gender differences in rate of cognitive decline in subjects at risk for Alzheimer’s disease. Alzheimer’s Dement. 2015;11:P817.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献